TGF-β receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-β/SMAD4 signaling pathway

Radiotherapy is used to treat gastric cancer (GC); however, radioresistance challenges the clinical outcomes of GC, and the mechanisms of radioresistance in GC remain poorly understood. Here, we report that the TGF-β receptor inhibitor, LY2109761 (LY), is a potential radiosensitizer both in vitro an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Tian, Huang, Tianhe, Zhang, Dongdong, Wang, Miao, Wu, Balu, Shang, Yufeng, Sattar, Safat, Ding, Lu, Liu, Yin, Jiang, Hongqiang, Liang, Yuxing, Zhou, Fuling, Wei, Yongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834415/
https://www.ncbi.nlm.nih.gov/pubmed/31631064
http://dx.doi.org/10.18632/aging.102329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834415/
https://www.ncbi.nlm.nih.gov/pubmed/31631064
http://dx.doi.org/10.18632/aging.102329

Ejemplares similares